Scancell Share Discussion Threads

[ruckrover] 06/10/2024 11:54

Inan,

"not sure what all that means ."

Yes, we've already established maths and statistics are not your strong points.

Anyway, off to the pub now for Sunday lunch so leave you to it.

[inanaco] 06/10/2024 11:53

go and buy that then .... Crick PLC

[ruckrover] 06/10/2024 11:52

Inan
"well the data must be so good we have not heard of them ATB Ruck"

The issue of your personal ignorance does not detract from the organisations achievements. They have products in trial (like Scancell), have an eminent management team (like Scancell) and are extremely well funded (unlike Scancell)

Director: Sir Paul Nurse, a Nobel Prize-winning geneticist, is the Director of the Francis Crick Institute.

Chief Operating Officer: Alan Penn is the Chief Operating Officer, overseeing the institute’s operational functions.

Chief Scientific Officer: Julian Downward, a prominent cancer researcher, serves as the Chief Scientific Officer.

Board of Trustees: The institute is governed by a Board of Trustees, which includes representatives from its founding partners and other distinguished individuals from the scientific community.

As for the number of employees, the Crick Institute employs around 1,500 staff, including scientists, support staff, and administrative personnel.

The Francis Crick Institute has received significant government funding. In 2022, the Medical Research Council (MRC), Cancer Research UK (CRUK), and Wellcome announced a combined investment of £1 billion to support the institute over the next seven years. This funding aims to secure the future of the UK as a scientific powerhouse and support the Crick’s world-leading biomedical research.

[inanaco] 06/10/2024 11:32

one other post you missed ,,,, your words not mine


""Do you really expect Scancell's market cap to jump from £30m to nearly £3.75 billion based on three proof of concept early stage clinical trials? Moreover you think it could be even higher with deals? """"

[inanaco] 06/10/2024 11:30

Bermuda ... oh so why did you use these words if you are such an expert on High Avidity and Immunobody




""""Also worth noting that Scancell simply don't have a vaccine platform that can be quickly developed and manufactured yet and at the moment speed is of the essence, hence the focus on mRNA vaccines.""""

anyway .... you could never answer

Which one has failed

Keytruda

or

SCIB1


which basically rendered you impotent


hence your continued waffle on "the industry risk"

but do carry on ....

[ruckrover] 06/10/2024 11:27

Sorry Bermuda, I missed the significance of your post. Are there any numbers from the original SCIB1 trial and the current combo trial that are comparable?

[inanaco] 06/10/2024 11:25

well the data must be so good we have not heard of them ATB Ruck

and

Best case, SCIB1 works in the 60% of the 50% SOC failures giving an extra 30 responders on the 50% that already work = 30. So BEST case 50+30=80%

not sure what all that means .... as the trials are not geared to show that

but the word Synergy is the key word

[ruckrover] 06/10/2024 11:04

Inan,

"do they have a vaccine in trial ? "

Yes, you need to do a bit of research:

Yes, many of the treatments and therapies developed at the Francis Crick Institute have progressed to clinical trials. Here are a few examples:

Cancer Immunotherapy: Various immunotherapy approaches, including those developed at the Crick, have entered clinical trials to evaluate their efficacy and safety in cancer patients.

Combination Therapies for Lung Cancer: The combination treatments involving KRAS inhibitors, SHP2 inhibitors, and immune checkpoint inhibitors have shown promising results in preclinical studies and are moving towards clinical trials.

GammaDelta Therapeutics: The therapies developed by GammaDelta Therapeutics, which focus on Gamma Delta T cells, are also undergoing clinical trials to determine their potential in treating different types of cancer.

[ruckrover] 06/10/2024 10:56

Marcus,

Yes, thanks for the link I watched it live and thought along the lines of Inan's post that some of the answers are already known.

Once I thought about the numbers...

SOC 50%
SCIB1 60% (original trial)

it occurred to me that the combo response rate is quite predicable.

Worst case, the 50% SOC responses are contained fully in the 60% Mono group. So response rate would remain at 60% (it couldn't be lower than the mono therapy)

Best case, SCIB1 works in the 60% of the 50% SOC failures giving an extra 30 responders on the 50% that already work = 30. So BEST case 50+30=80%

So, worst case 60%, best case 80%. Looks like the 70% target looks like a reasonable bet? Which would be a significant improvement on SOC.

Apart from iSCIB1 have there been and other improvements to SCIB1 since the original trial? The achieved 82-85% in the SCOPE trial could be as a result of these or just a result of the relatively small sample size. Can't wait for the data....

[bermudashorts] 06/10/2024 10:54

Inanaco,

If you're going to refer to my previous posts then please at least attempt to understand them and stick to the facts. To clarify yet again, I have never said that Scancell could not be a BioNTech. I said that wasn't the investment case for me and I am holding for other reasons. If you are holding waiting for Scancell to have over 5000 employees, its own manufacturing plants and a market cap approaching $30 billion then that's up to you, but please don't knock those who are holding for really promising clinical trial results and the potential of some activity on the deals front.

As for avidity - of course I believe that ImmunoBody generates high avidity T cells because Lindy Durrant has told us that's the case. Do I believe your posts that in turn means SCIB1 has no risk whatsoever attached to it - no absolutely not.

[marcusl2] 06/10/2024 10:37

Thanks for finding this Violin

Title

Probing the expression

and adhesion of glycans involved

in Helicobacter pylori infection

Authors

Daniel Sijmons1, Simon Collett1,2, Caroline Soliman1,3, Andrew J. Guy1,4, Andrew M. Scott5,6,

Lindy G. Durrant7,8, Aaron Elbourne1, Anna K. Walduck1,9* & Paul A. Ramsland1,10,11*



Helicobacter pylori infects approximately half the human population and has an unusual infective niche of the human stomach. Helicobacter pylori is a major cause of gastritis and has been classified as a group 1 carcinogen by the WHO. Treatment involves triple or quadruple antibiotic therapy, but antibiotic resistance is becoming increasingly prevalent. Helicobacter pylori expresses certain blood group related antigens (Lewis system) as a part of its lipopolysaccharide (LPS), which is thought to assist in immune evasion. Additionally, H. pylori LPS participates in adhesion to host cells alongside several adhesion proteins. This study profiled the carbohydrates of H. pylori reference strains (SS1 and 26695) using monoclonal antibodies (mAbs) and lectins, identifying interactions between two carbohydrate-targeting mAbs and multiple lectins.

[inanaco] 06/10/2024 10:28

Bermuda

I have no issues ... but then you never believed the posts on High Avidity ref SCIB1 no risk just waffle about Pharma overall risk factors along with Burble

you also engaged in selling down Scancell and confirming that we could never be a BioNtech

as a point of ref ....

"""Inanaco - you should offer your services to the Francis Crick Institute, you could save them a great deal of time and money."""

do they have a vaccine in trial ? if not why not ?

[the real lozan] 06/10/2024 10:26

"such small details attract small minds"
They did attract YOURS

[ruckrover] 06/10/2024 10:26

Inan,

I don't class the theft of someone's IP as a "small detail"
I certainly wouldn't like it if someone were to steal mine.

[inanaco] 06/10/2024 10:07

what ever ....

such small details attract small minds

[ruckrover] 06/10/2024 09:57

"don't need to steal it i own part of it ..2

I own shares in HSBC bank. That doesn't mean I can walk in to a branch and help myself to some cash.

[marcusl2] 06/10/2024 09:56

Yes Bermuda.

I think Lindy said in the past that we may need less CTLA-4 which as you know is the more toxic CPI.

[bermudashorts] 06/10/2024 09:50

marcus,

Really interesting, thanks for the link. Highlights why it's so important that combination therapies do not bring added toxicity and this is one of the SCIB1's major advantages.

Anything that can be done to reduce these dreadful side effects and prevent patients from undergoing treatment that will never work has to be a good thing. Great to see UK academia/life sciences tackling this issue.

[bermudashorts] 06/10/2024 09:35

Ruck - The objective response rate for SCIB1 as a monotherapy was 60% with stable disease, the ORR for doublet CPI therapy is the percentage of patients with partial or complete responses. There's a big difference.

Inanaco - you should offer your services to the Francis Crick Institute, you could save them a great deal of time and money.

[inanaco] 06/10/2024 09:26

don't need to steal it i own part of it .........

however Labour plays scatter cash .... ie 22bn in carbon capture !!



Response with SCIB1 mono therapy 60% ????????

[ruckrover] 06/10/2024 09:03

Inan, That was my initial thought as well. Response with current standard of care 50%Response with SCIB1 mono therapy 60%Response on SCOPE trial 70-85% (awaiting data to confirm)Above applies to melanoma and the study will investigate a number of other cancer types. As regards having a cheque, would you really steal Scancell's research and sell it?

[inanaco] 06/10/2024 08:29

easiest thing in the world to answer

Wrong T cells ======= Low avidity

can i have a cheque please Wes ?

[marcusl2] 06/10/2024 07:50

alongside 12 bioscience and technology companies.

So now a new multimillion-pound research programme aims to discover why at least half of all patients fail to respond to immunotherapy or suffer from those debilitating side effects.





Dominic Hughes
Health Correspondent at BBC News